Kura Oncology (NASDAQ:KURA) Given New $14.00 Price Target at UBS Group

Kura Oncology (NASDAQ:KURA - Free Report) had its price objective reduced by UBS Group from $27.00 to $14.00 in a report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also issued reports about the company. Jefferies Financial Group cut their price objective on Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a research report on Thursday, November 21st. TD Cowen reiterated a "buy" rating on shares of Kura Oncology in a research report on Thursday, November 21st. JMP Securities reiterated a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a research report on Thursday, February 6th. Cantor Fitzgerald upgraded Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. Finally, Bank of America dropped their price target on Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a research report on Friday, November 22nd. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Kura Oncology presently has an average rating of "Moderate Buy" and a consensus price target of $25.50.

Remove Ads

Kura Oncology Trading Down 2.2 %

Kura Oncology stock traded down $0.17 during trading hours on Thursday, reaching $7.53. The company had a trading volume of 1,291,397 shares, compared to its average volume of 1,591,525. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company has a 50-day moving average price of $8.00 and a 200 day moving average price of $13.29. The firm has a market cap of $608.09 million, a price-to-earnings ratio of -3.19 and a beta of 0.85. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. Equities analysts forecast that Kura Oncology will post -2.44 earnings per share for the current year.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the business's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now directly owns 88,253 shares of the company's stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Barclays PLC raised its stake in shares of Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company's stock worth $3,234,000 after purchasing an additional 84,563 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Kura Oncology in the fourth quarter worth $436,000. Moody Aldrich Partners LLC raised its stake in shares of Kura Oncology by 42.3% in the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company's stock worth $1,251,000 after purchasing an additional 42,712 shares during the last quarter. Harbor Capital Advisors Inc. raised its stake in shares of Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock worth $430,000 after purchasing an additional 2,076 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in shares of Kura Oncology in the fourth quarter worth $623,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.